Literature DB >> 32416134

The immunogenicity of an anti-EGFR single domain antibody (VHH) is enhanced by misfolded amorphous aggregation but not by heat-induced aggregation.

Md Golam Kibria1, Yoko Akazawa-Ogawa2, Nafsoon Rahman1, Yoshihisa Hagihara2, Yutaka Kuroda3.   

Abstract

Amorphous aggregates of therapeutic proteins can provoke an unwanted immune response (anti-drug antibodies; ADAs), but counter-examples have led to some controversy. Amorphous aggregates can possess unique biophysical and biochemical attributes depending on both the way they are generated and the protein's biophysical/biochemical properties. Here, we examine the immunogenicity of an anti-EGFR single domain antibody (VHH) in four types of amorphous aggregates: two heat-aggregated VHH incubated at 65 °C (VHH-65) and 95 °C (VHH-95), a misfolded VHH isolated from the insoluble fraction of the E. coli lysate (VHH-Ins), and a low solubility misfolded VHH produced by miss-shuffling the SS bonds of the native VHH (VHH-Mis). Biophysical and biochemical measurements indicated that VHH was indeed natively folded, monomeric, and β-sheeted; that VHH-65 was partially unfolded and formed aggregates with a Z-average (Zave) of 771 nm; whereas VHH-95 was unfolded and formed aggregates of 1722 nm; and that both VHH-Ins and VHH-Mis were misfolded with non-native intermolecular SS bonds and formed aggregates with a Zave of 1846 nm and 1951 nm, respectively. The IgG level generated in Jcl:ICR mice determined by ELISA showed that the native VHH was barely immunogenic, VHH-95 was not immunogenic, while VHH-65 was mildly immunogenic. By contrast, the misfolded aggregates, VHH-Ins and VHH-Mis, having a Zave and an aggregation propensity similar to that of VHH-95, were highly immunogenic. These findings indicate the critical role of the biochemical and biophysical attributes of the amorphous aggregates in generating an immune response against a protein, rather than just their sizes.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amorphous aggregation; Anti-drug antibodies; Disulfide bond; Immunogenicity; Protein aggregation; Protein misfolding; Protein solubility; SS bond; Single domain antibody

Mesh:

Substances:

Year:  2020        PMID: 32416134     DOI: 10.1016/j.ejpb.2020.05.006

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  6 in total

1.  Reverse Engineering Analysis of the High-Temperature Reversible Oligomerization and Amyloidogenicity of PSD95-PDZ3.

Authors:  Sawaros Onchaiya; Tomonori Saotome; Kenji Mizutani; Jose C Martinez; Jeremy R H Tame; Shun-Ichi Kidokoro; Yutaka Kuroda
Journal:  Molecules       Date:  2022-04-28       Impact factor: 4.927

Review 2.  Antibody variable region engineering for improving cancer immunotherapy.

Authors:  Hantao Lou; Xuetao Cao
Journal:  Cancer Commun (Lond)       Date:  2022-07-13

3.  Anti-EGFR VHH Antibody under Thermal Stress Is Better Solubilized with a Lysine than with an Arginine SEP Tag.

Authors:  Md Golam Kibria; Akari Fukutani; Yoko Akazawa-Ogawa; Yoshihisa Hagihara; Yutaka Kuroda
Journal:  Biomolecules       Date:  2021-05-29

Review 4.  Toward Drug-Like Multispecific Antibodies by Design.

Authors:  Manali S Sawant; Craig N Streu; Lina Wu; Peter M Tessier
Journal:  Int J Mol Sci       Date:  2020-10-12       Impact factor: 5.923

5.  Solubility Controlling Peptide Tags of Opposite Charges Generate a Bivalent Immune Response Against Dengue ED3 Serotypes 3 and 4.

Authors:  Nafsoon Rahman; Shiho Miura; Mami Okawa; Md Golam Kibria; Mohammad Monirul Islam; Yutaka Kuroda
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

6.  A systematic mutational analysis identifies a 5-residue proline tag that enhances the in vivo immunogenicity of a non-immunogenic model protein.

Authors:  Nafsoon Rahman; Mohammad Monirul Islam; Md Golam Kibria; Satoru Unzai; Yutaka Kuroda
Journal:  FEBS Open Bio       Date:  2020-08-30       Impact factor: 2.792

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.